|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
277:44021-44027
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains.
|
|
J.Valjakka,
A.Hemminki,
S.Niemi,
H.Söderlund,
K.Takkinen,
J.Rouvinen.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
A highly selective, high affinity recombinant anti-testosterone Fab fragment has
been generated by stepwise optimization of the complementarity-determining
regions (CDRs) by random mutagenesis and phage display selection of a monoclonal
antibody (3-C(4)F(5)). The best mutant (77 Fab) was obtained by evaluating the
additivity effects of different independently selected CDR mutations. The 77 Fab
contains 20 mutations and has about 40-fold increased affinity (K(d) = 3 x
10(-10) m) when compared with the wild-type (3-C(4)F(5)) Fab. To obtain
structural insight into factors, which are needed to improve binding properties,
we have determined the crystal structures of the mutant 77 Fab fragment with
(2.15 A) and without testosterone (2.10 A) and compared these with previously
determined wild-type structures. The overall testosterone binding of the 77 Fab
is similar to that of the wild-type. The improved affinity and specificity of
the 77 Fab fragment are due to more comprehensive packing of the testosterone
with the protein, which is the result of small structural changes within the
variable domains. Only one important binding site residue Glu-95 of the heavy
chain CDR3 is mutated to alanine in the 77 Fab fragment. This mutation,
originally selected from the phage library based on improved specificity,
provides more free space for the testosterone D-ring. The light chain CDR1 of 77
Fab containing eight mutations has the most significant effect on the improved
affinity, although it has no direct contact with the testosterone. The mutations
of CDR-L1 cause a rearrangement in its conformation, leading to an overall fine
reshaping of the binding site.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 6.
Fig. 6. Superposition of binding sites of the 77 Fab (top
panel) and wt Fab (bottom panel) in the free and
testosterone-bound form. The free structures are shown in pink,
and testosterone complex is shown in black. Stereopairs were
prepared with the Molscript program (29).
|
 |
Figure 7.
Fig. 7. The binding site in the 77 Fab (A) and in the wt
Fab (B) structures. The solvent-accessible surface was produced
using the O program (21).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2002,
277,
44021-44027)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.H.Niemi,
K.Takkinen,
L.K.Amundsen,
H.Söderlund,
J.Rouvinen,
and
M.Höyhtyä
(2011).
The testosterone binding mechanism of an antibody derived from a naïve human scFv library.
|
| |
J Mol Recognit,
24,
209-219.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Kobayashi,
and
H.Oyama
(2011).
Antibody engineering toward high-sensitivity high-throughput immunosensing of small molecules.
|
| |
Analyst,
136,
642-651.
|
 |
|
|
|
|
 |
D.Romanazzo,
F.Ricci,
G.Volpe,
C.T.Elliott,
S.Vesco,
K.Kroeger,
D.Moscone,
J.Stroka,
H.Van Egmond,
M.Vehniäinen,
and
G.Palleschi
(2010).
Development of a recombinant Fab-fragment based electrochemical immunosensor for deoxynivalenol detection in food samples.
|
| |
Biosens Bioelectron,
25,
2615-2621.
|
 |
|
|
|
|
 |
P.Pansri,
N.Jaruseranee,
K.Rangnoi,
P.Kristensen,
and
M.Yamabhai
(2009).
A compact phage display human scFv library for selection of antibodies to a wide variety of antigens.
|
| |
BMC Biotechnol,
9,
6.
|
 |
|
|
|
|
 |
A.Rothe,
B.E.Power,
and
P.J.Hudson
(2008).
Therapeutic advances in rheumatology with the use of recombinant proteins.
|
| |
Nat Clin Pract Rheumatol,
4,
605-614.
|
 |
|
|
|
|
 |
R.Barderas,
J.Desmet,
P.Timmerman,
R.Meloen,
and
J.I.Casal
(2008).
Affinity maturation of antibodies assisted by in silico modeling.
|
| |
Proc Natl Acad Sci U S A,
105,
9029-9034.
|
 |
|
|
|
|
 |
S.G.Park,
Y.J.Jung,
Y.Y.Lee,
C.M.Yang,
I.J.Kim,
J.H.Chung,
I.S.Kim,
Y.J.Lee,
S.J.Park,
J.N.Lee,
S.K.Seo,
Y.H.Park,
and
I.H.Choi
(2006).
Improvement of neutralizing activity of human scFv antibodies against hepatitis B virus binding using CDR3 V(H) mutant library.
|
| |
Viral Immunol,
19,
115-123.
|
 |
|
|
|
|
 |
M.B.Zwick,
H.K.Komori,
R.L.Stanfield,
S.Church,
M.Wang,
P.W.Parren,
R.Kunert,
H.Katinger,
I.A.Wilson,
and
D.R.Burton
(2004).
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
|
| |
J Virol,
78,
3155-3161.
|
 |
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2003).
A survey of the year 2002 commercial optical biosensor literature.
|
| |
J Mol Recognit,
16,
351-382.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |